Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Identification and Validation of VEGFR2 Kinase as a Target of Voacangine by a Systematic Combination of DARTS and MSI

Version 1 : Received: 1 February 2020 / Approved: 3 February 2020 / Online: 3 February 2020 (04:36:54 CET)

A peer-reviewed article of this Preprint also exists.

Kim, Y.; Sugihara, Y.; Kim, T.Y.; Cho, S.M.; Kim, J.Y.; Lee, J.Y.; Yoo, J.S.; Song, D.; Han, G.; Rezeli, M.; Welinder, C.; Appelqvist, R.; Marko-Varga, G.; Kwon, H.J. Identification and Validation of VEGFR2 Kinase as a Target of Voacangine by a Systematic Combination of DARTS and MSI. Biomolecules 2020, 10, 508. Kim, Y.; Sugihara, Y.; Kim, T.Y.; Cho, S.M.; Kim, J.Y.; Lee, J.Y.; Yoo, J.S.; Song, D.; Han, G.; Rezeli, M.; Welinder, C.; Appelqvist, R.; Marko-Varga, G.; Kwon, H.J. Identification and Validation of VEGFR2 Kinase as a Target of Voacangine by a Systematic Combination of DARTS and MSI. Biomolecules 2020, 10, 508.

Journal reference: Biomolecules 2020, 10, 508
DOI: 10.3390/biom10040508

Abstract

Although natural products are an important source of drugs and drug leads, identification and validation of their target proteins have proven difficult. Here, we report the development of a systematic strategy for target identification and validation employing drug affinity responsive target stability (DARTS) and mass spectrometry imaging (MSI) without modifying or labeling natural compounds. Through a validation step using curcumin, which targets aminopeptidase N (APN), we successfully standardized the systematic strategy. Using label-free voacangine, an antiangiogenic alkaloid molecule as the model natural compound, DARTS analysis revealed vascular endothelial growth factor receptor 2 (VEGFR2) as a target protein. Voacangine inhibits VEGFR2 kinase activity and its downstream signaling by binding to the kinase domain of VEGFR2, as was revealed by docking simulation. Through cell culture assays, voacangine was found to inhibit the growth of glioblastoma cells expressing high levels of VEGFR2. Specific localization of voacangine to tumor compartments in a glioblastoma xenograft mouse was revealed by MSI analysis. The overlap of histological images with the MSI signals for voacangine was intense in the tumor regions and showed colocalization of voacangine and VEGFR2 in the tumor tissues by immunofluorescence analysis of VEGFR2. The strategy employing DARTS and MSI to identify and validate the targets of a natural compound as demonstrated for voacangine in this study is expected to streamline the general approach of drug discovery and validation using other biomolecules including natural products.

Subject Areas

target identification; drug affinity responsive target stability (DARTS); mass spectrometry imaging (MSI); voacangine; curcumin; natural products

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.